1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
    Meeting Abstract

    Halfdanarson, T. R.; Halperin, D.; Reidy-Lagunes, D.; Kong, G.; Mailman, J.; Herrmann, K.; Sri Rajaskanthan, R.; Leyden, S.; Capdevila Castillon, J.; Sierras, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, L. S.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
    Meeting Abstract

    Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients
    Meeting Abstract

    Sherman, E. J.; Tsai, F.; Janku, F.; Allen, C.; Yaeger, R.; Ammakkanavar, N.; Butowski, N.; Michelson, G.; Paz, M.; Tussay-Lindenberg, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Pharmaceutical agents as potential drivers in development of early-onset colorectal cancer (EOCRC)
    Meeting Abstract

    Ben-Aharon, I.; Rotem, R.; Cercek, A.; Half, E.; Goshen-Lago, T. G.; Chodick, G.; Kelsen, D. P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
    Meeting Abstract

    Wu, C.; Strickler, J. H.; Cercek, A.; Siena, S.; AndreĢ, T.; Ng, K.; Van Cutsem, E.; Paulson, A. S.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez Fernandez, M. E.; Kuboki, Y.; Rasco, D.; Cecchini, M.; Shen, L.; Archuadze, S.; Geng, J.; Haderk, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Meeting Abstract

    Kuboki, Y.; Yaeger, R.; Fakih, M. G.; Strickler, J. H.; Masuishi, T.; Kim, E. J.; Bestvina, C. M.; Langer, C. J.; Krauss, J. C.; Puri, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Meeting Abstract

    Kopetz, S.; Murphy, D. A.; Pu, J.; Yaeger, R.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Alkuzweny, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Kasper, S.; Segal, N. H.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; Amirouchene Angelozzi, N.; Amirouchene da Silva, A. P.; St-Pierre, A.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save